Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Variability in Antinuclear Antibody Testing to Assess Patient Eligibility for Clinical Trials of Novel Treatments for Systemic Lupus Erythematosus.

Pisetsky DS, Thompson DK, Wajdula J, Diehl A, Sridharan S.

Arthritis Rheumatol. 2019 Sep;71(9):1534-1538. doi: 10.1002/art.40910. Epub 2019 Aug 5.

PMID:
31385442
2.

Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.

Wallace DJ, Strand V, Merrill JT, Popa S, Spindler AJ, Eimon A, Petri M, Smolen JS, Wajdula J, Christensen J, Li C, Diehl A, Vincent MS, Beebe J, Healey P, Sridharan S.

Ann Rheum Dis. 2017 Mar;76(3):534-542. doi: 10.1136/annrheumdis-2016-209668. Epub 2016 Sep 26.

3.

Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis.

Constantin T, Foeldvari I, Vojinovic J, Horneff G, Burgos-Vargas R, Nikishina I, Akikusa JD, Avcin T, Chaitow J, Koskova E, Lauwerys BR, Calvo Penades I, Flato B, Gamir ML, Huppertz HI, Jaller Raad JJ, Jarosova K, Anton J, Macku M, Otero Escalante WJ, Rutkowska-Sak L, Trauzeddel R, Velez-Sanchez PJ, Wouters C, Wajdula J, Zang C, Bukowski J, Woodworth D, Vlahos B, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO).

J Rheumatol. 2016 Apr;43(4):816-24. doi: 10.3899/jrheum.150430. Epub 2016 Mar 1.

PMID:
26932344
4.

Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study.

Maksymowych WP, Dougados M, van der Heijde D, Sieper J, Braun J, Citera G, Van den Bosch F, Logeart I, Wajdula J, Jones H, Marshall L, Bonin R, Pedersen R, Vlahos B, Kotak S, Bukowski JF.

Ann Rheum Dis. 2016 Jul;75(7):1328-35. doi: 10.1136/annrheumdis-2015-207596. Epub 2015 Aug 12.

5.

Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial.

Dougados M, van der Heijde D, Sieper J, Braun J, Maksymowych WP, Citera G, Miceli-Richard C, Wei JC, Pedersen R, Bonin R, Rahman MU, Logeart I, Wajdula J, Koenig AS, Vlahos B, Alvarez D, Bukowski JF.

Arthritis Rheumatol. 2014 Aug;66(8):2091-102. doi: 10.1002/art.38721.

6.

Pharmacokinetics, efficacy and safety profiles of etanercept monotherapy in Japanese patients with rheumatoid arthritis: review of seven clinical trials.

Takeuchi T, Miyasaka N, Kawai S, Sugiyama N, Yuasa H, Yamashita N, Sugiyama N, Wagerle LC, Vlahos B, Wajdula J.

Mod Rheumatol. 2015 Mar;25(2):173-86. doi: 10.3109/14397595.2014.914014. Epub 2014 May 20. Review.

7.

Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis.

van der Heijde D, Zack D, Wajdula J, Sridharan S, Koenig AS.

Scand J Rheumatol. 2014;43(1):49-53. doi: 10.3109/03009742.2013.834961. Epub 2013 Nov 1.

PMID:
24182312
8.

Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.

Horneff G, Burgos-Vargas R, Constantin T, Foeldvari I, Vojinovic J, Chasnyk VG, Dehoorne J, Panaviene V, Susic G, Stanevica V, Kobusinska K, Zuber Z, Mouy R, Rumba-Rozenfelde I, Breda L, Dolezalova P, Job-Deslandre C, Wulffraat N, Alvarez D, Zang C, Wajdula J, Woodworth D, Vlahos B, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO).

Ann Rheum Dis. 2014 Jun;73(6):1114-22. doi: 10.1136/annrheumdis-2012-203046. Epub 2013 May 21.

9.

A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis.

Takeuchi T, Miyasaka N, Zang C, Alvarez D, Fletcher T, Wajdula J, Yuasa H, Vlahos B.

Mod Rheumatol. 2013 Jul;23(4):623-33. doi: 10.1007/s10165-012-0742-6. Epub 2012 Sep 26.

PMID:
23011358
10.

Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan.

Mori M, Takei S, Imagawa T, Imanaka H, Nerome Y, Higuchi R, Kawano Y, Yokota S, Sugiyama N, Yuasa H, Fletcher T, Wajdula JS.

Mod Rheumatol. 2012 Sep;22(5):720-6. doi: 10.1007/s10165-011-0578-5. Epub 2012 Jan 4.

PMID:
22212889
11.

Etanercept in the treatment of disease-modifying anti-rheumatic drug (DMARD)-refractory polyarticular course juvenile idiopathic arthritis: experience from Japanese clinical trials.

Mori M, Takei S, Imagawa T, Imanaka H, Nerome Y, Kurosawa R, Kawano Y, Yokota S, Sugiyama N, Yuasa H, Fletcher T, Wajdula JS.

Mod Rheumatol. 2011 Dec;21(6):572-8. doi: 10.1007/s10165-011-0450-7. Epub 2011 Apr 11.

PMID:
21479889
12.

Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis.

Klareskog L, Gaubitz M, Rodríguez-Valverde V, Malaise M, Dougados M, Wajdula J; Etanercept Study 301 Investigators.

Clin Exp Rheumatol. 2011 Mar-Apr;29(2):238-47. Epub 2011 Apr 19.

PMID:
21418785
13.

Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications.

Gottlieb AB, Gordon K, Giannini EH, Mease P, Li J, Chon Y, Maddox J, Weng HH, Wajdula J, Lin SL, Baumgartner SW.

J Drugs Dermatol. 2011 Mar;10(3):289-300.

PMID:
21369647
14.

Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial.

Holgate ST, Noonan M, Chanez P, Busse W, Dupont L, Pavord I, Hakulinen A, Paolozzi L, Wajdula J, Zang C, Nelson H, Raible D.

Eur Respir J. 2011 Jun;37(6):1352-9. doi: 10.1183/09031936.00063510. Epub 2010 Nov 25.

15.

Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.

Reich K, Segaert S, Van de Kerkhof P, Durian C, Boussuge MP, Paolozzi L, Wajdula J, Boggs R.

Dermatology. 2009;219(3):239-49. doi: 10.1159/000237871. Epub 2009 Sep 10.

PMID:
19752505
16.

Etanercept in the longterm treatment of patients with ankylosing spondylitis.

Dijkmans B, Emery P, Hakala M, Leirisalo-Repo M, Mola EM, Paolozzi L, Salvarani C, Sanmarti R, Sibilia J, Sieper J, Van Den Bosch F, van der Heijde D, van der Linden S, Wajdula J.

J Rheumatol. 2009 Jun;36(6):1256-64. doi: 10.3899/jrheum.081033. Epub 2009 May 1. Erratum in: J Rheumatol. 2010 Oct;37(10):2198.

PMID:
19411393
17.

Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study.

Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, Pavelka K, Sambrook PN, Smolen JS, Khandker R, Singh A, Wajdula J, Fatenejad S; Etanercept European Investigators Network.

Ann Rheum Dis. 2009 Jul;68(7):1146-52. doi: 10.1136/ard.2007.087106. Epub 2008 Sep 15.

18.

Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.

van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L, Wajdula J.

Br J Dermatol. 2008 Nov;159(5):1177-85. doi: 10.1111/j.1365-2133.2008.08771.x. Epub 2008 Jul 31.

PMID:
18673365
19.

Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis.

van der Heijde D, Klareskog L, Landewé R, Bruyn GA, Cantagrel A, Durez P, Herrero-Beaumont G, Molad Y, Codreanu C, Valentini G, Zahora R, Pedersen R, MacPeek D, Wajdula J, Fatenejad S.

Arthritis Rheum. 2007 Dec;56(12):3928-39.

20.

Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.

Braun J, McHugh N, Singh A, Wajdula JS, Sato R.

Rheumatology (Oxford). 2007 Jun;46(6):999-1004. Epub 2007 Mar 27.

PMID:
17389658
21.

Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.

van der Heijde D, Da Silva JC, Dougados M, Geher P, van der Horst-Bruinsma I, Juanola X, Olivieri I, Raeman F, Settas L, Sieper J, Szechinski J, Walker D, Boussuge MP, Wajdula JS, Paolozzi L, Fatenejad S; Etanercept Study 314 Investigators.

Ann Rheum Dis. 2006 Dec;65(12):1572-7. Epub 2006 Sep 12.

22.

Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison.

Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, Pavelka K, Sambrook PN, Smolen JS, Wajdula J, Fatenejad S; Etanercept European Investigators Network (Etanercept Study 309 Investigators).

Ann Rheum Dis. 2006 Oct;65(10):1357-62. Epub 2006 Apr 10.

23.

Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.

van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, Tornero-Molina J, Wajdula J, Pedersen R, Fatenejad S; TEMPO Study Investigators.

Arthritis Rheum. 2006 Apr;54(4):1063-74.

24.

A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs.

Klareskog L, Gaubitz M, Rodriguez-Valverde V, Malaise M, Dougados M, Wajdula J; Etanercept Study 301 Investigators.

Ann Rheum Dis. 2006 Dec;65(12):1578-84. Epub 2006 Mar 15.

25.

Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.

Zhou H, Mayer PR, Wajdula J, Fatenejad S.

J Clin Pharmacol. 2004 Nov;44(11):1235-43.

PMID:
15496641
26.

Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis.

Zhou H, Buckwalter M, Boni J, Mayer P, Raible D, Wajdula J, Fatenejad S, Sanda M.

Int J Clin Pharmacol Ther. 2004 May;42(5):267-76.

PMID:
15176649
27.

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.

Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martín Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators.

Lancet. 2004 Feb 28;363(9410):675-81.

PMID:
15001324
28.

A food interaction study of bromfenac, naproxen sodium, and placebo in cesarean section patients.

Sunshine A, Olson NZ, Zighelboim I I, Wajdula JS.

Prim Care Update Ob Gyns. 1998 Jul 1;5(4):195.

PMID:
10838371
29.

A dose-ranging study of bromfenac sodium in oral surgery pain.

Hersh EV, Cooper SA, Levin LM, Betts NJ, Wedell D, Lamp C, Wajdula J.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 Jul;86(1):36-41.

PMID:
9690243

Supplemental Content

Loading ...
Support Center